REG-4basebio Plc: RBC Capital Markets initiates research coverage

4BasebioAnnouncement

14/03/2025 07:15

14 March 2025

   
     


4basebio PLC

("4basebio" or the "Company")

RBC Capital Markets initiates research coverage
 

Cambridge, UK, 14 March 2025 - 4basebio PLC (AIM: 4BB), an innovation-led
provider of novel synthetic DNA products and a non-viral, thermostable nucleic
acid delivery platform, announces that RBC Capital Markets has initiated
research coverage of the Company, which can be found on the Company’s
website https://www.4basebio.com/investors/analyst-coverage/.

For further enquiries, please contact:

 4basebio PLC Dr. Heikki Lanckriet, CEO                                                              +44 (0)1223 967 943  
 Nominated Adviser        Cairn Financial Advisers LLP Jo Tuner / Sandy Jamieson / Ed Downes         +44 (0)20 7213 0880  
 Joint Broker RBC Capital Markets Rupert Walford / Max Avison / Kathryn Deegan                       +44 (0)20 7653 4000  
 Joint Broker Cavendish Capital Markets Limited Geoff Nash / Nigel Birks                             +44 (0)20 7220 0500  

Notes to Editors

About 4basebio

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused
on accelerating the development of advanced therapy medicinal products (ATMPs)
through its high-performance synthetic DNA products and non-viral, cell
targeting nucleic acid delivery platform. The Company’s objective is to
become a market leader in the manufacture and supply of high-quality synthetic
DNA products for research, therapeutic and pharmacological use as well as
development of target specific non-viral vectors for the efficient delivery of
payloads in patients.

Forward-looking statements

This announcement may contain certain statements about the future outlook for
4basebio.  Although the directors believe their expectations are based on
reasonable assumptions, any statements about future outlook may be influenced
by factors that could cause actual outcomes and results to be materially
different.



Copyright (c) 2025 PR Newswire Association,LLC. All Rights Reserved